Buscar

Estamos realizando la búsqueda. Por favor, espere...

Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors

Abstract: During resolution of inflammation, specialized proresolving mediators (SPMs), including resolvins, are produced to restore tissue homeostasis. We hypothesized that there might be a dysregulation of SPMs pathways in pathological vascular remodeling and that resolvin D2 (RvD2) might prevent vascular remodeling and contractile and endothelial dysfunction in a model of obesity and hypertension. In aortic samples of patients with or without abdominal aortic aneurysms (AAA), we evaluated gene expression of enzymes involved in SPMs synthesis (ALOXs), SPMs receptors and pro-inflammatory genes. In an experimental model of aortic dilation induced by high fat diet (HFD, 60%, eighteen weeks) and angiotensin II (AngII) infusion (four weeks), we studied the effect of RvD2 administration in aorta and small mesenteric arteries structure and function and markers of inflammation. In human macrophages we evaluated the effects of AngII and RvD2 in macrophages function and SPMs profile. In patients, we found positive correlations between AAA and obesity, and between AAA and expression of ALOX15, RvD2 receptor GPR18, and pro-inflammatory genes. There was an inverse correlation between the expression of aortic ALOX15 and AAA growth rate. In the mice model, RvD2 partially prevented the HFD plus AngII-induced obesity and adipose tissue inflammation, hypertension, aortic and mesenteric arteries remodeling, hypercontratility and endothelial dysfunction, and the expression of vascular proinflammatory markers and cell apoptosis. In human macrophages, RvD2 prevented AngII-induced impaired efferocytosis and switched SPMs profile. RvD2 might represent a novel protective strategy in preventing vascular damage associated to hypertension and obesity likely through effects in vascular and immune cells.

 Fuente: Biomedicine & Pharmacotherapy, 2024, 174, 116564

 Editorial: Editions Scientifiques Elsevier

 Año de publicación: 2024

 Nº de páginas: 20

 Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.biopha.2024.116564

 ISSN: 0753-3322,1950-6007

 Proyecto español: SAF2016-80305P

 Url de la publicación: https://doi.org/10.1016/j.biopha.2024.116564

Autoría

RODRIGUES-DIEZ, RAQUEL

BALLESTEROS-MARTÍNEZ, CONSTANZA

MORENO-CARRILES, ROSA MARÍA

DÍAZ DEL CAMPO, LUCÍA S.

CACHOFEIRO, VICTORIA

DALLI, JESMOND

GARCÍA-REDONDO, ANA B.

REDONDO, JUAN M.

SALAICES, MERCEDES

BRIONES, ANA M.